Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 1
1995 1
1997 1
1998 3
1999 3
2000 2
2001 2
2002 1
2003 1
2004 5
2005 3
2006 7
2007 3
2008 1
2009 2
2010 2
2011 4
2012 5
2013 3
2014 1
2015 6
2016 4
2017 1
2018 4
2019 5
2020 5
2021 6
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Musolino A, et al. Among authors: pegram md. J Immunother Cancer. 2022 Jan;10(1):e003171. doi: 10.1136/jitc-2021-003171. J Immunother Cancer. 2022. PMID: 34992090 Free PMC article. Review.
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.
Cui L, Gouw AM, LaGory EL, Guo S, Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, Bazhin AA, Chen M, Hu L, Xie J, Fang M, Zhang C, Zhu Q, Wang Z, Giaccia AJ, Gambhir SS, Zhu W, Felsher DW, Pegram MD, Goun EA, Le A, Rao J. Cui L, et al. Among authors: pegram md. Nat Biotechnol. 2021 Mar;39(3):357-367. doi: 10.1038/s41587-020-0707-9. Epub 2020 Oct 19. Nat Biotechnol. 2021. PMID: 33077961 Free PMC article.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: pegram md. JAMA Oncol. 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. JAMA Oncol. 2021. PMID: 33480963 Free PMC article. Clinical Trial.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: pegram md. J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332179 Free PMC article. Clinical Trial.
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. Sikic BI, et al. Among authors: pegram md. J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811285 Free PMC article. Clinical Trial.
Induced pluripotent stem cells as a novel cancer vaccine.
Wang L, Pegram MD, Wu JC. Wang L, et al. Among authors: pegram md. Expert Opin Biol Ther. 2019 Nov;19(11):1191-1197. doi: 10.1080/14712598.2019.1650909. Epub 2019 Aug 12. Expert Opin Biol Ther. 2019. PMID: 31364894 Review.
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL. Upton R, et al. Among authors: pegram md. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. doi: 10.1073/pnas.2026849118. Proc Natl Acad Sci U S A. 2021. PMID: 34257155 Free PMC article.
80 results